Cite this answer
Ipamorelin vs CJC-1295: Selective Ghrelin Mimetic vs GHRH Analog: quick citable summary
This PeptaHub comparison summarizes Ipamorelin and CJC-1295 side by side, covering category, legal status, primary route, half-life, mechanism, and editorial verdict for writers and AI answer engines.
PeptaHub. “Ipamorelin vs CJC-1295: Selective Ghrelin Mimetic vs GHRH Analog.” peptahub.com, 2026. https://peptahub.com/compare/ipamorelin-vs-cjc-1295. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/compare/ipamorelin-vs-cjc-1295.
Head-to-head comparison
| Property | Ipamorelin | CJC-1295 |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Research Only | Research Only |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~2 hours | ~30 minutes (no DAC) / ~8 days (with DAC) |
| Mol. Weight | 711.85 Da | 3,367.97 Da |
| Side Effects | Headache, Flushing, Injection site pain | Flushing, Headache, Dizziness |
Key differences
- Mechanism: Ipamorelin is a selective ghrelin/GHS-R1a receptor agonist that triggers pulsatile GH release through calcium/IP3 signaling; CJC-1295 is a GHRH analog that binds the GHRH receptor on pituitary somatotrophs, activating the cAMP/PKA/CREB pathway to stimulate both GH synthesis and secretion.
- Half-life: Ipamorelin has a half-life of approximately 2 hours; CJC-1295 without DAC (Mod GRF 1-29) has a half-life of 30 minutes to 2 hours, while CJC-1295 with DAC covalently binds serum albumin to achieve a half-life of 5.8-8.1 days.
- GH release pattern: Ipamorelin produces discrete GH pulses that return to baseline within roughly 2 hours; CJC-1295 with DAC produces a sustained GH bleed — mean GH rises 2-10-fold for 6 or more days, with IGF-1 elevated 1.5-3-fold for 9-11 days after a single injection (Teichman et al., JCEM, 2006).
- Pulsatility: Ipamorelin's short half-life preserves natural pulse rhythms and receptor sensitivity between doses; CJC-1295 with DAC preserved pulse frequency and magnitude in the one human study to measure it, but basal (trough) GH rose 7.5-fold — lifting mean GH 46% and IGF-1 45% by raising the floor between pulses rather than amplifying the peaks (Ionescu and Frohman, JCEM, 2006).
- Hormonal selectivity: Ipamorelin did not raise ACTH, cortisol, or prolactin in the swine study that characterized it (Raun et al., 1998), a selectivity profile GHRP-2 and GHRP-6 do not share; CJC-1295's documented effects — transient injection-site erythema in trials, with water retention, headache, and flushing at higher research doses — are consistent with GH/IGF-1 elevation rather than off-target hormone release.
- Dosing: Research protocols for ipamorelin typically use 200-300 mcg subcutaneously 2-3 times daily; CJC-1295 without DAC is studied at 100-300 mcg per injection, often at the same injection as ipamorelin, while the DAC form is typically administered once weekly.
- Evidence base: CJC-1295 with DAC has randomized, double-blind, ascending-dose human pharmacology data in healthy adults (Teichman et al., 2006); ipamorelin's dose-dependent GH release is established in rat and swine studies, and its one phase 2 trial (postoperative ileus, n=114) missed its primary endpoint. No human trial has measured body composition outcomes for either peptide.
- Legal status: Both are research-only compounds on the FDA's Category 2 bulk drug substances list and cannot legally be compounded in the US; neither was among the 12 peptides removed from Category 2 on April 15, 2026, and both are prohibited in sport under WADA Section S2.
The verdict
Ipamorelin and CJC-1295 are better understood as complements than competitors — they stimulate the same pituitary somatotrophs through different receptors, which is precisely why research protocols so often pair them. Ipamorelin contributes a short, selective GH pulse with minimal cortisol or prolactin involvement (established in animal studies); CJC-1295 contributes GHRH-receptor stimulation, either as synchronized daily pulses (without DAC) or as a sustained weekly elevation of GH and IGF-1 (with DAC). On evidence, CJC-1295 with DAC holds the stronger human pharmacology data, while ipamorelin's clinical record is thinner than its reputation suggests. Neither peptide has human trials demonstrating body-composition outcomes, and both remain research-only compounds under FDA Category 2 restrictions.
Frequently asked questions
Yes — this is the most common pairing in GH secretagogue research. Because ipamorelin acts on the ghrelin/GHS-R1a receptor and CJC-1295 acts on the GHRH receptor, the two pathways use different second messengers (calcium/IP3 and cAMP) that converge on the same GH secretory granules. Combined GH output is reported to be 2-3x greater than either peptide alone, and the pairing more closely mimics the natural dual-signal GH pulse. No controlled trials have formally studied the combination.
Research protocols that prioritize pulsatile GH release use CJC-1295 without DAC (Mod GRF 1-29), whose 30-minute to 2-hour half-life overlaps ipamorelin's roughly 2-hour window so both peptides are active at the pituitary simultaneously. CJC-1295 with DAC is typically administered once weekly and produces sustained baseline elevation instead of synchronized pulses, which some researchers view as less physiological. The choice reflects the tradeoff between pulse fidelity and dosing convenience.
They are selective in different senses. Ipamorelin is selective among hormones: in the swine study that characterized it (Raun et al., 1998), it released GH without raising ACTH, cortisol, or prolactin — unlike GHRP-2 and GHRP-6, which raise cortisol and ACTH alongside GH. CJC-1295 is selective by design at the GHRH receptor but acts within the broader GH/IGF-1 axis; its documented side effects are consistent with GH/IGF-1 elevation rather than off-target hormone release.
No, but it changes the baseline. In the only human study to measure this directly (Ionescu and Frohman, JCEM, 2006), overnight 20-minute sampling showed that pulse frequency and magnitude were unaltered one week after a single CJC-1295 injection. What changed was basal (trough) GH, which rose 7.5-fold, lifting mean GH by 46% and IGF-1 by 45%. The DAC form raises the floor between pulses rather than amplifying the pulses themselves.
Both are research-only compounds with no FDA-approved indication. Both were placed on the FDA's Category 2 bulk drug substances list in September 2023, which put them outside enforcement discretion for compounding, and neither was among the 12 peptides removed from that list on April 15, 2026. Both are prohibited in competitive sport under WADA Section S2. Verify current federal and state rules before relying on access claims.